Projects per year
Personal profile
Education
- 1985-1989 Ph.D., Graduate Institute of Medical Sciences, National Defense Medical Center
- 1976-1983 M.D., School of Medicine, National Defense Medical Center
Experience
- 2020.11- Professor, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University
- 2018.11- Deputy Director, Taipei Cancer Center, Taipei Medical University
- Director, Division of Oncology, Department of Internal Medicine, College of Medicine, Taipei Medical University
- 2018.02- Professor, International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University
- 2016.11-2017.10 Professor, International Master/Ph.D. Program in Medicine, College of Medicine, Taipei Medical University
- 2015.10-2019.07.31 Deputy Director, Department of Human Research, Taipei Medical University
- 2015.02- Chief, Department of Medical Affairs, Shuang Ho Hospital, Taipei Medical University
- 2014.02-2016.07 Director, Joint Clinical Research Center, Taipei Medical University
- 2010.10- Chief and Professor, Division of Hematology/Oncology, Shuang-Ho Hospital, Taipei Medical University,
- 2010.10-2015.01 Chief and Professor, Division of Internal Medicine, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan
- 2010.09- Professor, Graduate Institute of Clinical Medicine, Taipei Medical University
- 2010.05- Director, Division of Oncology, Tri-Service General Hospital
- 1997.08-2010.09 Chief and Professor, Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical Center,
- 1992.08-2010.09 Attending Physician, Division of Hematology/Oncology, Tri-Service General Hospital
- 1989.07-1997.07 Associate Professor, National Defense Medical Center
- 1987-1789 Research Fellow, Department of Immunology and Biochemistry Research, Roswell Park Memorial Institute,
- 1983.08-1992.07 Resident, Chief Resident, Fellow, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center
- 1983.08-1989.06 Teaching Assistant, National Defense Medical Center
Awards
- 2019 Distinguished Clinical Trial Leader Award, Taipei Medical University
- 2008 The best 100 physicians of Taiwan
- 2005 Teacher of the year, National Defense University
- 2001 Remarkable physician of Tri-Service General Hospital
- 2000 Teacher of the year, National Defense Medical Center. September
- 1998 Decent Man, Tri-Service General Hospital
- 1997 International Who's Who of Contemporary Achievement, Hall of Fame, awarded by the American Biographical Institute
- 1996 Men of Achievement, 17th edition, published by The International Biographical Center, Cambridge, England
- 1994 Outstanding Military Physician honored by the Ministry of Defense, Taiwan, R. O. C.
- 1994-1995 Scholarship of Biomedical Science for physician awarded by Academia Sinica, Taiwan, R. O. C.
- 1993 Distinguished Youth of Taipei City
- 1992 Remarkable physician of Tri-Service General Hospital
- 1989 First class Academic Medal, awarded by Ministry of Defense, R. O. C.
- 1983 Second class Academic Medal, awarded by Ministry of Defense, R. O. C.
Research Interests
- Dr. Chao’s current researchinterests focus on clinical trials and translational studies. The clinical trials he involves are about the development of new drugs or strategies in treating cancers and hematological disorders. In translational studies, his major effort is on the development of a novel biochemical marker, i.e. tartrate-resistant acid phosphatase 5b, in the diagnosis and monitoring of metastatic bone disease of breast cancer. He also intends to define the role and search the potential usefulness of tartrate-resistant acid phosphatase 5a in macrophage-related disorders.
Fingerprint
Dive into the research topics where Tsu-Yi Chao is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Investigation of the Diagnostic and Therapeutic Value to Novel Ferroptotic Biomarkers in Double Hit Lymphoma( I )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
研究BTK/HER2信號通路在HER2陽性乳腺癌生物特性角色: 調控T細胞的效應及逆轉賀癌平抗藥性的分子機制(3/3)
8/1/21 → 7/31/22
Project: A - Government Institution › b - Ministry of Science and Technology
-
研究BTK/HER2信號通路在HER2陽性乳腺癌生物特性角色: 調控T細胞的效應及逆轉賀癌平抗藥性的分子機制(2/3)
8/1/20 → 7/1/21
Project: A - Government Institution › b - Ministry of Science and Technology
-
研究BTK/HER2信號通路在HER2陽性乳腺癌生物特性角色：調控T細胞的效應及逆轉賀癌平抗藥性的分子機制
1/1/20 → 12/31/20
Project: A - Government Institution › a - National Health Research Institutes
-
Investigating the Role of Btk/Her2 Signaling as a Therapeutic Target for Restoration of T Cell Function and Reversal of Trastuzumab Resistance in Her2+ Breast Cancer(1/3)
8/1/19 → 7/31/20
Project: A - Government Institution › b - Ministry of Science and Technology
-
Synergistic disruption of BTK and BCL-2 causes apoptosis while inducing ferroptosis in double-hit lymphoma
Setiawan, S. A., Liu, W. Z., Weng, PW. W., Lee, C. H., Yadav, V. K., Hardianti, M. S., Yeh, C. T. & Chao, T. Y., Mar 15 2023, In: European Journal of Pharmacology. 943, 175526.Research output: Contribution to journal › Article › peer-review
-
142P Effectiveness and safety of pegylated liposomal doxorubicin- cyclophosphamide vs. epirubicin-cyclophosphamide as adjuvant chemotherapy for stage I and II HER2-negative breast cancer: An interim analysis of phase II randomized trial
Tseng, L-M., Chen, F-M., Chen, S-T., Cheng, T-F., Chao, T-Y., Dai, M-S., Kao, W-Y., Chen, D-R., Liu, L-C., Wang, H. C., Chang, H-T., Wang, B. W., Yu, J-C., Chen, S. C., Liao, K-H. & Hou, M-F., 2022, In: Annals of Oncology. 33, p. S604Research output: Contribution to journal › Article › peer-review
-
A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors. Journal of Clinical Oncology
Ho, C-L., Chao, T-Y., Chang, C. L., Lin, H. Y., Yang, F., Wang, Q. & Zhu, J., 2022, In: Journal of Clinical Oncology. 40, 16_suppl, p. e14560-e14560Research output: Contribution to journal › Article › peer-review
-
Cancer-Associated Exosomal CBFB Facilitates the Aggressive Phenotype, Evasion of Oxidative Stress, and Preferential Predisposition to Bone Prometastatic Factor of Breast Cancer Progression
Hsu, C. H., Ma, H. P., Ong, J. R., Hsieh, M. S., Yadav, V. K., Yeh, C. T., Chao, T. Y., Lee, W. H., Huang, W. C., Kuo, K. T., Fong, I. H., Lin, C. C. & Su, C. M., 2022, In: Disease Markers. 2022, 8446629.Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus) -
Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients
Lin, P. H., Chen, S. C., Tseng, L. M., Chang, K. J., Huang, A. C., Cheng, K. C., Yang, K., Wu, H. C., Chao, T. Y., Chang, Y. C., Lin, P. C., Kuo, W. H., Kuo, W. L., Lin, C. H., Chen, H. M., Yeh, D. C., Liu, L. C., Liu, C. Y., Wang, M. Y., Lo, C., & 2 others, Apr 2022, In: Breast Cancer Research and Treatment. 192, 3, p. 629-637 9 p.Research output: Contribution to journal › Article › peer-review
Datasets
-
Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo
Chen, J. (Creator), Huang, W. (Contributor), Bamodu, O. A. (Contributor), Chang, P. M. (Creator), Chao, T. (Contributor) & Huang, T. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4558895.v1, https://springernature.figshare.com/collections/Monospecific_antibody_targeting_of_CDH11_inhibits_epithelial-to-mesenchymal_transition_and_represses_cancer_stem_cell-like_phenotype_by_up-regulating_miR-335_in_metastatic_breast_cancer_in_vitro_and_in_vivo/4558895/1
Dataset
-
Additional file 1: Table S1. of A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors
Wang, C. (Creator), Chen, L. (Contributor), Chiang, N. (Contributor), Yeh, C. G. (Contributor), Hsieh, R. (Contributor), Chao, T. (Contributor) & Wang, Y. (Creator), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3646481_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3646481_d1.v1
Dataset
-
A phase I clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment
Liu, K. (Contributor), Chao, T. (Contributor), Chang, J. (Contributor), Cheng, A. (Contributor), Ch'Ang, H. (Contributor), Kao, W. (Contributor), Wu, Y. (Creator), Yu, W. (Contributor), Chung, T. (Contributor) & Whang-Peng, J. (Creator), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3612833.v1, https://doi.org/10.6084%2Fm9.figshare.c.3612833.v1
Dataset
-
Additional file 1: of Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo
Chen, J. (Creator), Huang, W. (Contributor), Bamodu, O. A. (Contributor), Chang, P. M. (Creator), Chao, T. (Contributor) & Huang, T. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8341985.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Monospecific_antibody_targeting_of_CDH11_inhibits_epithelial-to-mesenchymal_transition_and_represses_cancer_stem_cell-like_phenotype_by_up-regulating_miR-335_in_metastatic_breast_cancer_in_vitro_and_in_vivo/8341985/1
Dataset
-
Additional file 1: of Potential effects of valproate and oxcarbazepine on growth velocity and bone metabolism in epileptic children- a medical center experience
Lai, C. (Contributor), Fan, H. (Contributor), Chu, D. (Contributor), Wang, C. (Contributor), Chen, S. (Contributor), Chao, T. (Contributor) & Lin, C. (Contributor), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3630170_d1.v1, https://doi.org/10.6084%2Fm9.figshare.c.3630170_d1.v1
Dataset